Breast cancer (BC) remains one of the leading causes of mortality among women, with triple-
negative breast cancer (TNBC) standing out for its aggressive nature and limited treatment …

Abstract Treatment of patients with triple-negative breast cancer (TNBC) has been
challenging due to the absence of well-defined molecular targets and the highly invasive …

Breast cancers possess fundamentally altered metabolism that fuels their pathogenicity.
While many metabolic drivers of breast cancers have been identified, the metabolic …

To date, no targeted therapies are available to treat triple negative breast cancer (TNBC),
while other breast cancer subtypes are responsive to current therapeutic treatment …

Metabolic dysregulation is a prominent feature in breast cancer, but it remains poorly
characterized in patient tumors. In this study, untargeted metabolomics analysis of triple …

Triple-negative breast cancer (TNBC) remains an unmet medical challenge. We investigated
metabolic dysregulation in TNBCs by using our multi-omics database (n= 465, the largest to …

Abstract Treatment and relevant targets for breast cancer (BC) remain limited, especially for
triple-negative BC (TNBC). We identified 6091 proteins of 76 human BC cell lines using data …

There is growing evidence that docetaxel, a microtubule-targeting agent like the other
taxane paclitaxel, induces dual cytotoxicity mechanism according to dose level …

Triple negative breast cancers (TNBC) are aggressive malignancies for which
chemotherapy is the only treatment option. Many TNBC acquire chemotherapy resistance …

Triple-negative breast cancer (TNBC), which is largely synonymous with the basal-like
molecular subtype, is the 5th leading cause of cancer deaths for women in the United States …